Language selection

Government of Canada / Gouvernement du Canada

Search

Re-evaluation Note REV2024-01, Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2024-2029

Pest Management Regulatory Agency
3 May 2024
ISSN: 1925-0649 (PDF version)
Catalogue number: H113-5/2024-1E-PDF (PDF version)

Table of contents

Background

The purpose of this document is to inform registrants, pesticide regulatory officials and the Canadian public of the re-evaluation and special review work (in other words, the post-market reviews) planned by Health Canada's Pest Management Regulatory Agency (PMRA) for the next five fiscal years from 1 April 2024 to 31 March 2029.

This work plan includes the target dates for the proposed and final decisions to be published since 1 April 2024, the status of all open re-evaluations and special reviews, as well as new re-evaluations expected to be initiated from 1 April 2024 to 31 March 2029. This document presents updates to the information last published in Re-evaluation Note REV2023-01, Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2023-2028.

Health Canada regulates pesticides in Canada, with the primary objective of protecting the health of Canadians and the environment. A pesticide product may only be sold or used in Canada if it has been registered or otherwise authorized under the authority of the Pest Control Products Act. Health Canada uses a rigorous science-based risk assessment approach to ensure that the product meets health and environmental protection standards and has value.

As part of the post-market program, registered pesticides are re-evaluated on a cyclical basis to determine their continued acceptability. Pesticides may also be re-evaluated as a result of changes in the information required or the procedures used by Health Canada to determine that the pesticide meets current health, environment and value standards. The re-evaluation process is described in Regulatory Directive DIR2016-04, Management of Pesticides Re-evaluation Policy. In addition, a special review may be initiated at any time to address the identified aspect(s) of concern, and a special review is triggered only under certain circumstances. Special reviews differ from re-evaluations in that a special review is intended to examine only specific aspects of a pesticide. Additional information on special reviews can be found in the PMRA Guidance Document, Approach to Special Reviews of Pesticides.

As required under the Pest Control Products Act, Health Canada publishes all post-market proposed decisions for public consultation. Following consultation, comments and information submitted by the public and other stakeholders are considered before Health Canada issues a final decision. Stakeholders are encouraged to stay informed of upcoming consultations and decisions for pesticides by visiting the Pesticides and pest management section of Canada.ca.

This five-year work plan may change in response to workload and emerging issues that require priority action. While this work plan will be updated annually, during the course of the year, interested stakeholders can monitor the PMRA's Public Registry to view the announcement of new re-evaluations and special reviews, as well as other documents relevant to specific post-market reviews.

Part A – Current re-evaluation and special review work plan (Tables 1–3)

The post-market review program workload remains significant. In recent years, Health Canada focused its resources on the completion of the remaining older pesticide active ingredients registered before 1995, and completed their re-evaluation by 31 March 2023. Health Canada introduced the risk based prioritization for the re-evaluation program in 2019 (REV2020-01), and ongoing efforts to streamline the re-evaluation processes for lower priority actives resulted in the removal of the backlog of lower priority actives. The re-evaluation reviews of several higher priority actives have been delayed due to the demands of focusing resources on completing the re-evaluations of older pesticides, and other priorities including responding to litigations, as well as notices of objection, and the scientific complexity associated with certain pesticide reviews. The number of re-evaluation initiations currently required as per the 15-year legislative requirement continues to be high and given the current resource capacity considerations, the backlog is growing.

As part of its Transformation Agenda (PMRA Transformation), the PMRA is building upon existing risk prioritization efforts to develop a proportional effort approach that prioritizes workload across the full pesticide program. Implementation of proportional effort will enable the PMRA to better focus review efforts to increase overall protection and make progress to eliminate the re-evaluation backlog. The proportional effort policy is expected to be issued for public consultation in mid-summer 2024. Future work plans will reflect any new prioritization or timelines, once the proportional effort policy is finalized.

In addition to proportional effort, the PMRA has recently consulted on the continuous oversight lifecycle approach (Proposed Continuous Oversight Policy) that enhances our ability to keep pace with new science information and takes necessary action where needed to protect human health and the environment. A final continuous oversight approach taking into consideration the comments received during consultation is expected to be issued in late Spring 2024. Continuous oversight reduces reliance on the re-evaluation program by identifying and addressing risks sooner thereby decreasing the complexity of re-evaluation reviews.

During the post-market reviews, when necessary, Health Canada will seek independent scientific advice through Science Advisory Committee to better inform its evidence-based decisions.

Part A, Table 1 Targets for consultation and final decisions of special reviews
Active ingredient name Target date of consultationFootnote 1
Chlorpropham Q3 (2025–26)
Desmedipham Q4 (2027–28)

Dicamba

  • Dicamba (present as acid, ester, salts)
  • Dicamba (present as n,n-bis(3-aminopropyl)methylamine salt)
  • Dicamba (present as monoethanolamine salt)
  • Dicamba (present as n-(2-aminoethyl)-1,2-ethanediamine salt)
  • Dicamba (present as acid)
  • Dicamba (present as potassium salt)
  • Dicamba (present as sodium salt)
  • Dicamba (present as dimethylamine salt)
  • Dicamba (present as diglycolamine salt)
  • Dicamba (present as isopropylamine salt)
  • Dicamba (present as diethanolamine salt)
 January 2025
Ethofumesate Q4 (2026–27)
Glufosinate ammonium Q1 (2026–27)

Hydantoins

  • Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related hydantoins
  • Available bromine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related hydantoins
  • Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin, 1,3-dichloro-5,5-dimethylhydantoin, 1,3-dichloro-5-ethyl-5-methylhydantoin and related hydantoins
  • Available Chlorine Present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3- Dichloro-5-Ethyl-5-Methylhydantoin
 Q3 (2025–26)
Iodocarb (3-iodo-2-propynyl butyl carbamate) October 2024

MCPA

  • MCPA (present as acid)
  • MCPA (present as amine salts: diethanolamine, dimethylamine, or mixed amines)
  • MCPA (present as esters)
  • MCPA (present as potassium salt or as sodium salt)
 Q3 (2025–26)
Novaluron Q1 (2025-26)
Propiconazole Q1 (2026–27)
Pydiflumetofen November 2024
Thiacloprid Q4 (2026–27)
Active ingredient name Target date of final decisionFootnote 1
Atrazine Q2 (2025–26)
Chlorothalonil March 2025
Fosetyl aluminum August 2024
Methyl bromide Consultation started 28 March 2024

Footnotes

Footnote 1

Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

Return to footnote 1 referrer
Part A, Table 2a Targets for consultation and final re-evaluation decisions
Active ingredient name Re-evaluation category Target dateFootnote 1
Proposed re-evaluation decisions Target date of consultation
6-Benzylaminopurine 1 Q2 (2026–27)
3-Methyl-2-Cyclohexen-1-one 3 September 2024
Acetamiprid 1 Q2 (2026–27)
Bensulide 1 Q1 (2027–28)

Carbon dioxide cluster:

  • Carbon dioxide gas
  • Liquid carbon dioxide
 2 October 2024
Cellulose 3 January 2025
Clothianidin general re-evaluationFootnote 2 1 Q2 (2025–26)
Cyprodinil 1 Q4 (2025–26)
D-cis, trans-allethrin 1 Q2 (2026–27)
DEET plus related active toluamides 1 Q1 (2025–26)
Famoxadone 1 February 2025

Fatty Acid cluster:

  • Potassium Salts of Fatty Acids
  • Triethanolamine Salts of Fatty Acids
  • Fatty Acids
  • Ammonium Salt of Fatty Acid
 2 January 2025
Fenamidone 1 Q1 (2025–26)
Ferric Sodium Ethylenediaminetetraacetic Acid 3 Q1 (2025–26)
Fluazinam 1 Q4 (2025–26)
German Cockroach Extract 3 March 2025

Gibberellins cluster:

  • Gibberellic acid
  • Gibberellins A4A7
 3 Q1 (2025–26)
Glufosinate ammonium 1 Q1 (2026–27)

Mecoprop cluster:

  • Mecoprop-P (present as Acid)
  • Mecoprop-P (present as Dimethylamine Salt)
  • Mecoprop-P (present as Potassium Salt)
 1 Q3 (2025–26)
Methoxyfenozide 1 Q4 (2026–27)
Naled 1 Q3 (2026–27)
Nonylphenoxypolyethoxyethanol 3 March 2025
Phorate 1 Q3 (2026–27)
Picolinafen 1 Q3 (2027–28)
Potassium bicarbonate 2 February 2025

Rodenticide Cluster:

  • Brodifacoum
  • Bromadiolone
  • Bromethalin
  • Chlorophacinone
  • Diphacinone (present in free form or as sodium salt)
  • Warfarin (present in free form or as sodium salt)
  • Zinc phosphide
  • Difethialone
 1 Q2 (2026–27)
Spinetoram 1 Q2 (2025–26)
Spinosad 1 Q2 (2025–26)
Streptomyces lydicus strain WYEC108 3 December 2024
Sulphur 2 March 2025
Tetrachlorvinphos 1 Q2 (2027–28)
Thiacloprid 1 Q4 (2026–27)
Thiamethoxam general re-evaluationFootnote 2 1 Q2 (2025–26)
Cumulative Health Risk Assessment: N-Methyl Carbamates 1 Q4 (2025–26)
Cumulative Health Risk Assessment: OrganophosphatesFootnote 3 (project plan) 1 October 2024
Final re-evaluation decisions Target date of final decision
Abamectin 1 Q1 (2025–26)
Agrobacteriumradiobacter strain K84 and K1026 3 June 2024
Azoxystrobin 1 Q2 (2026–27)
Flufenacet 1 August 2024
Foramsulfuron 3 Consultation started 28 March 2024
Methyl bromide 1 Consultation started 28 March 2024
Natamycin 3 Consultation started 6 March 2024
Octenol 3 June 2024

Silicon dioxide cluster:

  • Silica aerogel
  • Silicon dioxide
 3 August 2024
Sodium chloride 3 May 2024
S-metolachlor and R-enantiomer 1 Consultation started 29 February 2024
Tebuconazole 1 September 2024

Footnotes

Footnote 1

Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

Return to footnote 1 referrer

Footnote 2

Cyclical re-evaluations of clothianidin and thiamethoxam were initiated in 2016 to assess their value, as well as human health and environmental risks other than impacts on pollinators and aquatic invertebrates. The assessment of the impacts on pollinators was completed in 2019. Special reviews of clothianidin and thiamethoxam related to aquatic invertebrates were completed in March 2021. Special reviews of clothianidin, thiamethoxam and imidacloprid related to squash bees were completed in February 2022.

Return to footnote 2 referrer

Footnote 3

A separate project plan will be published as per process described in Science Policy Note SPN2018-02, Cumulative Health Risk Assessment Framework.

Return to footnote 3 referrer

Part A, Table 2b Status of other active ingredients (currently in early stage of re-evaluation process)

The re-evaluations of the following active ingredients are in the early stage of the re-evaluation process, and Health Canada will provide an updated status in the next work plan to be published in spring 2025:

Active ingredient name Current status
1,2-Dibromo-2,4-Dicyanobutane Scoping phase completed
2-(Hydroxymethyl)-2-nitro-1,3-propanediol Scoping phase completed
2-(Thiocyanomethylthio)benzothiazole Scoping phase
10,10'-Oxybis (Phenoxarsine) Scoping phase completed
Acifluorfen, present as sodium salt Scoping phase

Dioxaborinanes cluster:

  • 2,2-(1-Methyltrimethylenedioxy)bis-(4-methyl1,3,2-dioxaborinane)
  • 2,2-Oxybis(4,4,6-trimethyl-1,3,2-dioxaborinane)
 Scoping phase
Acequinocyl Scoping phase

Aminopyralid

  • Aminopyralid
  • Aminopyralid triisopropanolamine salt
  • Aminopyralid potassium salt
 Scoping phase
Ammonium Bromide Scoping phase

Antimicrobials cluster:

  • 2,2-Dibromo-3-nitrilopropionamide
  • 2-Methyl-4-isothiazolin-3-one
  • 5-Chloro-2-methyl-4-isothiazolin-3-one
  • 4,5-Dichloro-2-N-Octyl-3(2H)-Isothiazolone
  • Bronopol
  • Methylene bis(thiocyanate)
 Scoping phase
Atrazine (plus related active Triazines) Scoping phase

Triazinetrione cluster:

  • Available Chlorine, present as Sodium Dichloro-S-Triazinetrione
  • Available Chlorine, present as Trichloro-S-Triazinetrione
  • Trichloro-S-Triazinetrione
 Scoping phase

Bentazon cluster:

  • Bentazon (present as Sodium Salt)
  • Bentazone
 Scoping phase
Bifenazate Scoping phase completed
Bispyribac-Sodium (KIH-2023) Scoping phase
Boscalid Scoping phase completed
Bromacil (present in free form, as dimethylamine salt, or as lithium salt) Scoping phase
Carbendazim Scoping phase
Carfentrazone-ethyl Scoping phase
Chlorpropham Scoping phase
Clomazone Scoping phase
Cyazofamid Scoping phase
Daminozide Scoping phase completed
Dichlobenil Scoping phase
Didecyldimethylammonium (present as Carbonate and Bicarbonate Salts) Scoping phase
Diflubenzuron Scoping phase
Diphenylamine Scoping phase
Diuron Scoping phase

Endothal cluster:

  • Endothal
  • Endothal, present as N,N-dimethylalkylamine salt
 Scoping phase
EPTC (S-ethyl N,N-dipropylcarbamothioate) Scoping phase
Etridiazole Scoping phase
Fenbutatin Oxide Scoping phase

Fish toxicants cluster:

  • 4-Nitro-3-(trifluoromethyl) phenol sodium salt
  • Niclosamide
 Scoping phase completed
Fluvalinate-tau Scoping phase
Iodosulfuron-methyl-sodium Scoping phase completed
Ipconazole Scoping phase completed
Mesotrione Scoping phase completed

Metalaxyl cluster:

  • Metalaxyl
  • Metalaxyl-M and S-Isomer
 Scoping phase
Metribuzin Scoping phase
Napropamide Scoping phase
Novaluron Scoping phase
Oxamyl Scoping phase
Oxyfluorfen Scoping phase
Pinoxaden Scoping phase
Prohexadione calcium Scoping phase
Prometryne Plus Related Active Triazines Scoping phase
Prothioconazole Scoping phase
Pyrimethanil Scoping phase
Pyraclostrobin Scoping phase completed
Pyrasulfotole Scoping phase
Pyroxsulam Scoping phase
Rotenone Scoping phase
Sethoxydim Scoping phase
(S)-Methoprene Scoping phase
Spirodiclofen Scoping phase
Spiromesifen Scoping phase

Sulfonyl Ureas cluster:

  • Chlorsulfuron
  • Ethametsulfuron-Methyl
  • Metsulfuron-Methyl
  • Nicosulfuron
  • Rimsulfuron
  • Thifensulfuron-Methyl
 Scoping phase
Sulfuryl fluoride Scoping phase
Terbacil Scoping phase
Topramezone Scoping phase
Triallate Scoping phase
Triclopyr (present as butoxyethyl ester) Scoping phase
Trifloxystrobin Scoping phase completed

Part A, Table 3 Re-evaluation Initiations between 1 April 2024 and 31 March 2025

For the re-evaluation initiations between 1 April 2024 to 31 March 2025, risk-based prioritization of actives as higher or lower priority based on the risk prioritization approach implemented since 2019 (REV2020-01) was not conducted. As part of the PMRA's transformation initiative, a proportional effort policy is expected to be issued for consultation in mid-summer 2024, and prioritisation of re-evaluations initiated from 1 April 2024 onwards will be part of this proportional effort approach.

To further improve transparency for stakeholders and registrants, specific month of initiation of re-evaluation is included.

Active ingredient Initiation dates
1,2-Benzisothiazolin-3-one To be initiated July 2024

2,4-D cluster

  • 2,4-D (present as Acid)
  • 2,4-D (present as Amine Salts: Dimethylamine Salt, Diethanolamine Salt, or Other Amine Salts)
  • 2,4-D (present as choline salt)
  • 2,4-D (present as Low Volatile Esters)
 To be initiated May 2024

2-Phenylphenol and Salts cluster:

  • 2-Phenylphenol
  • 2-Phenylphenol (present as Potassium Salt)
  • 2-Phenylphenol (present as Sodium Salt)
 To be initiated April 2024

Alkyl Dimethyl Benzyl Ammonium Chloride Cluster (ADBAC):

  • N-Alkyl (25% C12, 60% C14, 15% C16) Dimethyl Benzyl Ammonium Chloride
  • N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Chloride
  • N-Alkyl (68% C12, 32% C14) Dimethyl Ethylbenzyl Ammonium Chloride
  • N-Alkyl (5% C12, 60% C14, 30% C16, 5% C18) Dimethyl Benzyl Ammonium Chloride
  • N-Alkyl (67% C12, 25% C14, 7% C16, 1% C18) Dimethyl Benzyl Ammonium Chloride
  • Diisobutylphenoxyethoxyethyl Dimethyl Benzyl Ammonium Chloride
  • N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Saccharinate
  • N-Dialkyl (5% C12, 60% C14, 30% C16, 5% C18) Methyl Benzyl Ammonium Chloride
 To be initiated March 2025

Bacillus thuringiensis cluster:

  • Bacillus thuringiensis Berliner ssp. kurstaki Strain HD-1
  • Bacillus thuringiensis Serotype H-14
  • Bacillus thuringiensis ssp. tenebrionis
 To be initiated May 2024
Beauveria bassiana Strain HF23 To be initiated April 2024
Bromoxynil To be initiated May 2024
Chlorantraniliprole To be initiated May 2024
Chlorthal (present as Dimethyl Ester) To be initiated August 2024
Clonostachys rosea strain J1446 To be initiated April 2024
Cloransulam-Methyl To be initiated September 2024
Coniothyrium minitans Strain CON/M/91-08 To be initiated March 2025
Cyprosulfamide To be initiated November 2024

Dicamba cluster:

  • Dicamba (present as Acid)
  • Dicamba (present as Acid, Ester, Salts)
  • Dicamba (present as Diethanolamine Salt)
  • Dicamba (present as Diglycoamine Salt)
  • Dicamba (present as Dimethylamine Salt)
  • Dicamba (present as Isopropylamine Salt)
  • Dicamba (present as Monoethanolamine Salt)
  • Dicamba (present as N-(2-Aminoethyl)-1,2-Ethanediamine Salt)
  • Dicamba (present as N,N-Bis(3-Aminopropyl)Methylamine Salt)
  • Dicamba (present as Potassium Salt)
  • Dicamba (present as Sodium Salt)
 To be initiated August 2024

Didecyl Dimethyl Ammonium Chloride Cluster (DDAC):

  • Didecyl Dimethyl Ammonium Chloride – Other
  • Didecyldimethylammonium (present as carbonate and icarbonate Salts)
  • Dioctyl Dimethyl Ammonium Chloride (present as Carbonate and Bicarbonate Salts)
  • Octyl Decyl Dimethyl Ammonium Chloride
  • Oxydiethylene Bis(Alkyl Dimethyl Ammonium Chloride)
 To be initiated March 2025
Dodine To be initiated May 2024
Ethofumesate To be initiated April 2024
Flumioxazin To be initiated March 2025
Glutaraldehyde To be initiated January 2025
Imazapyr To be initiated April 2024
Maleic Hydrazide To be initiated January 2025
Mandipropamid To be initiated August 2024

MCPA cluster:

  • MCPA (present as Acid)
  • MCPA (present as Amine Salts: Diethanolamine, Dimethylamine, or Mixed Amines)
  • MCPA (present as Esters)
  • MCPA (present as Potassium Salt or as Sodium Salt)
 To be initiated May 2024
Metaldehyde To be initiated November 2024
Metarhizium brunneum Strain F52 To be initiated February 2025
Mineral Oil To be initiated August 2024

Phosphonic acid cluster:

  • Mono- and Di-Potassium Salt of Phosphorous Acid
  • Mono- and Di-basic Sodium, Potassium, and Ammonium Phosphites
 To be initiated September 2024
Naphthalene Acetic Acid (present as Ethyl Ester, Sodium Salt, or as Ammonium Salt) To be initiated February 2025
Oxirane Derivatives - 50% Minimum To be initiated April 2024
Ozone To be initiated November 2024
Pendimethalin To be initiated June 2024

Picloram cluster:

  • Picloram (present as Potassium Salt)
  • Picloram (present as Acid)
  • Picloram (present as Amine Salts)
 To be initiated January 2025
Propylene Glycol To be initiated August 2024
Pyrazon To be initiated April 2024

Industrial Uses of Sodium Chlorite and Sodium Chlorate cluster:

  • Sodium Chlorite
  • Sodium Chlorate
 To be initiated April 2024
Spirotetramat To be initiated June 2024
Streptomycin To be initiated July 2024
Sulfentrazone To be initiated May 2024
Tetrakis hydroxymethyl phosphonium sulphate To be initiated May 2024
Thiencarbazone-Methyl To be initiated November 2024
Triazole Cumulative Risk Assessment To be initiated October 2024

Part B – Re-evaluation initiations anticipated between April 2025 and March 2029

The initiation date of the re-evaluation of a particular active ingredient is based on the date of its initial registration, or the date of the last completed re-evaluation.

Part B, Table 1 Re-evaluation Initiations between 1 April 2025 and 31 March 2026

The month in which the re-evaluation for the active ingredients to be initiated between 1 April 2025 to 31 March 2026 is also provided to further improve transparency for registrants and stakeholders.

Active Ingredient Initiation dates
Beauveria bassiana Strain GHA To be initiated June 2025
Bifenthrin To be initiated February 2026
Carbathiin To be initiated June 2025
Chlormequat Chloride To be initiated March 2026
Desmedipham To be initiated October 2025
Diazinon To be initiated November 2025
Dimethenamid-P To be initiated April 2025
Dithiopyr To be initiated September 2025
Formetanate Hydrochloride To be initiated April 2025
Hexazinone To be initiated April 2025
Imazamethabenz-Methyl To be initiated April 2025
Lime Sulphur Or Calcium Polysulphide To be initiated May 2025

N-Coco-Alkyltrimethylene Diamines present as:

  • Monobenzoate Salt
  • Alkyl-1,3-Propylene Diamine Acetates
  • 1-Alkylamino-3-Aminopropane (Alkyl Groups As Derived From Coconut Oil Fatty Acids)
 To be initiated December 2025

N-Decanol

N-Octanol

 To be initiated September 2025
Nosema (Paranosema) locustae Canning To be initiated April 2025
Oxycarboxin To be initiated June 2025
Phenmedipham To be initiated September 2025
Propyzamide To be initiated September 2025
Pseudomonas fluorescens A506 To be initiated July 2025
Tribenuron-Methyl To be initiated June 2025
Trifluralin To be initiated September 2025
R-(-)-1-Octen-3-Ol To be initiated December 2025
Saflufenacil To be initiated February 2026
Simazine Plus Related Active Triazines To be initiated March 2026
Verticillium albo-atrum, Isolate Wcs850 To be initiated October 2025

Part B, Table 2 Future re-evaluation initiations between 1 April 2026 and 31 March 2029

1 April 2026 to 31 March 2027

Active Ingredient

  • Diquat
  • Iron (present as FeHEDTA)
  • Tembotrione
  • Naphthalene
  • Animal repellent cluster:
    • Castor Oil
    • Dried Eggs
    • Fish Meal Mixture
    • Fish Oil Mixture
    • Garlic Oil
    • Meat Meal Mixture
    • Wintergreen Oil
  • Pseudomonas syringae – Strain ESC-10
  • Lactobacillus casei Strain LPT-111
  • Lactococcus lactis ssp. lactis Strain Ll64/CSL
  • Lactococcus lactis ssp. lactis Strain Ll102/CSL
  • Lactic Acid
  • Citric Acid
  • Mesosulfuron-Methyl
  • Metrafenone
  • Butoxypolypropylene Glycol
  • Paradichlorobenzene
  • Tefluthrin
  • Flonicamid
  • Acibenzolar-S-Methyl
  • Iodocarb (3-iodo-2-propynyl butyl carbamate)
  • Tralkoxydim
  • Thiabendazole
  • 1,4-Dimethylnaphthalene
  • Diclorprop cluster:
    • Dichlorprop-P
    • Dichlorprop-P (present as Dimethylamine Salt)
    • Dichlorprop P-Isomer (present as 2-Ethylhexyl Ester)
  • Thymol
  • Lactobacillus rhamnosus Strain LPT-21
  • Lactococcus lactis ssp. cremoris Strain M11/CSL
  • Imazethapyr
  • Sodium Fluoride
  • Trimethoxysilyl quats cluster:
    • 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trimethoxysilsyl quats)
    • 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trihydroxysilyl quats)
  • Diodofon
  • Hexahydro-1,3,5-Tris(2-Hydroxyethyl)-S-Triazine
  • Oxalic Acid Dihydrate
  • D-Limonene
  • Saponins Of Chenopodium Quinoa

1 April 2027 to 31 March 2028

Active Ingredient

  • Arsenic Acid
  • Available Bromine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
  • Available Chlorine present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin
  • Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
  • Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5-Ethyl-5-Methylhydantoin and Related Hydantoins
  • Bacillus firmus I-1582
  • Chromic Acid
  • Clopyralid
  • Copper (present as Basic Copper Carbonate)
  • Copper (present as Copper 8-Quinolinolate)
  • Copper (present as Copper Naphthenate)
  • Creosote
  • Cydia pomonella granulovirus (Strain M)
  • Extract of Reynoutria sachalinensis
  • Fluopicolide
  • Formaldehyde
  • Icaridin
  • Indaziflam
  • Metofluthrin
  • Oriental Mustard Seed Meal
  • Paecilomyces fumosoroseus Strain FE 9901
  • Paraformaldehyde
  • Penflufen
  • Penthiopyrad
  • Phoma Macrostoma
  • Propiconazole
  • Trichoderma asperellum Strain T34
  • Zinc (present as Zinc Oxide)
  • Zinc as Elemental (present as Zinc Naphthenate)

1 April 2028 to 31 March 2029

Active Ingredient

  • Ametoctradin
  • Ammonia (present as Ammonium Sulfate)
  • Aureobasidium pullulans cluster:
    • Aureobasidium pullulans Strain DSM 14940 and DSM 14941
    • Aureobasidium pullulans Strain DSM 14940
    • Aureobasidium pullulans Strain DSM 14941
  • Bacillus subtilis var. amyloliquefaciens Strain FZB24
  • Clavibacter michiganesis spp. michiganensis Bacteriophage
  • Cloquintocet-Mexyl
  • Denatonium Benzoate
  • Ethalfluralin
  • Fenoxaprop-P-Ethyl
  • Fluazifop-P-Butyl and S-Isomer
  • Fluopyram
  • Fluoxastrobin
  • Fluxapyroxad
  • Kasugamycin (Present as Hydrochloride Hydrate)
  • Malathion
  • MCPB cluster:
    • MCPB
    • MCPB (present as Sodium Salt)
  • Mint oil cluster:
    • Cornmint Oil
    • Methyl Salicylate
  • Octadecadien-1-ol cluster:
    • (E,Z)-2,13-Octadecadien-1-yl Acetate
    • (Z,Z)-3,13-Octadecadien-1-ol
    • (E,Z)-3,13-Octadecadien-1-ol
  • Picoxystrobin
  • Poly[Oxyethylene(Dimethyliminio)Ethylene (Dimethyliminio)Ethylene Dichloride]
  • Potassium Dimethyldithiocarbamate Salts
  • Pseudomonas fluorescens Strain CL145A
  • Pyroxasulfone
  • Sedaxane
  • Sulfoxaflor
  • Tetraconazole
  • Trichoderma virens Strain G-41

Page details

Date modified: